An alternative to epinephrine autoinjectors that can be delivered by a nasal spray is close to approval in Europe after being recommended for approval by the EMA’s human medicines committee.The new product, ARS Pharma’s EURneffy, is poised to become the first intranasal formulation of epinephrine to reach the market in the EU for emergency treatment of a life-threatening allergic reaction (anaphylaxis).
